Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Dynamic Cerebral Embolic Protection (CEP) medical device to address the devastating and costly problem of stroke during the large and growing number of heart valve procedures that occur annually around the world, such as Transcatheter Aortic Valve Replacement (TAVR).

• Point-Guard Protected™ Transcatheter Aortic Valve Replacement offers an innovative solution for complete Cerebral Embolic Protection (CEP) of the Brain.  POINT-GUARD™ achieves two required goals for protecting the patients Brain from stroke and addressing the unmet clinical need:

  1. Stroke during TAVR is high unpredictable and devastating when it occurs, which is the most feared patient complication.  POINT-GUARD™ provides Full Arch and Maximum Coverage of all Great Arch Vessels and inlets leading to the Brain.

  2. POINT-GUARD™ addresses the immediate need to safeguard the patient’s brain by filtering and deflecting Embolic Debris (Particles) traveling to the Brain, that could cause embolic brain lesions and which could result in a cerebral infraction or catastrophic stroke.

The Company’s mission is to minimize or eliminate the risk of stroke through full-arch and maximum filter protection from cerebral embolic debris and embolism during cardiac procedures.